Masarykova Univerzita

6 trials 1 recruiting Academic / non-commercial

Filter these 6 trials by condition, phase, country and more.

Open in Search →

6 Registered trials

1 Recruiting

4 Completed trials

1 Countries active

8 Unique IMPs

100% Results reported

Phase II

Phase I/II

Phase IV

Phase II: 2 Phase I/II: 2 Phase IV: 2

100%

4 of 4 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Chronic myeloid leukaemia (in remission) 1 Schizophrenia 1

Top IMPs

ALLOGENEIC ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS EXPANDED 1 ALLOGENEIC FAECAL MICROBIOTA 1 CAFFEINE CITRATE 1 DASATINIB 1 IMATINIB 1 MURCIDENCEL 1 NILOTINIB 1

All trials

6 total

Effect of faecal microbiota transplant on the expression of autism spectrum disorder core symptoms in children – open-label phase II clinica… Pending

2025-524673-16-00 Phase II 1 country ALLOGENEIC FAECAL MICROBIOTA
Caffeine administration for preterms in nociception outcomes Recruiting

2025-523475-33-00 Phase IV 1 country CAFFEINE CITRATE
A Prospective Phase II Clinical Trial Evaluating the Efficacy and the Safety of Tyrosine Kinase Inhibitors Withdrawal After a Previous Two-s… Ended

2024-514592-17-00 Phase II 1 country DASATINIB; IMATINIB; NILOTINIB
Safety and efficacy of olanzapine treatment in psychosis: Effect of genetic and epigenetic factors – covariates of treatment response Ended

2022-502902-33-00 Phase IV 1 country
Safety and efficacy of allogenic adipose tissue-derived mesenchymal stromal cells in patients with epidermolysis bullosa: Clinical trial pha… Ended

2024-516614-37-00 Phase I/II 1 country ALLOGENEIC ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS EXPANDED
Combined antitumor therapy with ex vivo manipulated dendritic cells producing interleukin-12 in children, adolescents and young adults with … Ended

2024-516613-21-00 Phase I/II 1 country MURCIDENCEL

Showing 1–6 of 6 trials

← All sponsors A–Z